Contact information
+44 (0)1865 857240
Tracey Walker
patoruryholman@dtu.ox.ac.uk
https://orcid.org/0000-0002-1256-874X
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, OXFORD. OX3 7LJ
Rury Holman
MB, ChB. FRCP(Lon). FMedSci
Emeritus Professor of Diabetic Medicine
- Emeritus Diabetes Trials Unit Director
- Emeritus NIHR Senior Investigator
- Honorary Consultant Physician
Rury Holman trained in medicine at the University of Bristol and was appointed Honorary Consultant Physician to the University of Oxford NHS Hospitals Trust in 1985, at which time he founded the University of Oxford Diabetes Trials Unit. He was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998 and as the founding Academic Chairman of the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) in 2003. He is a Fellow of the Academy of Medical Sciences, an Emeritus NIHR Senior Investigator and Emeritus Professor of Diabetic Medicine. Professor Holman has won many distinguished international awards including the ADA Harold Rifkin Award for Distinguished International Service, the ADA Outstanding Achievement in Clinical Diabetes Research Award, the Diabetes UK Banting Memorial Lecture, the Diabetes UK Robert Turner Award for Research Impact and the ADA Banting Medal for Scientific Achievement Award.
Recent publications
-
The Science of Diabetes and a Life of Trials: The 2024 Banting Medal for Scientific Achievement Award Lecture.
Journal article
Holman RR., (2025), Diabetes, 74, 164 - 174
-
The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.
Journal article
Adler AI. et al, (2025), Lancet, 405
-
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction.
Journal article
Marx N. et al, (2024), Eur Heart J, 45, 5117 - 5126
-
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).
Journal article
Lin B. et al, (2024), Lancet Diabetes Endocrinol
-
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Journal article
Neves JS. et al, (2024), Eur J Heart Fail